Biocon: The Heavy Lifting Is Done. What's Next?

When people think of Biocon, they usually think of a pharmaceutical company. But that's only part of the story.

Biocon is actually one of the world's largest biotechnology companies, with leadership in biosimilars and insulin. Today, it operates across biologics, biosimilars, generics, and research services, with products reaching more than 120 countries.

The company is among the top five global biosimilar players, one of the top three insulin companies, and also ranks among the world's top 15 companies in biomanufacturing capacity.

Yet despite its scale, the biggest driver of Biocon's future isn't its size; it's biosimilars.

The Opportunity That Could Drive the Next Decade:

Unlike generics, which are copies of traditional chemical drugs, biosimilars are highly similar versions of biologic medicines produced using living cells. They are significantly more complex to manufacture, creating higher barriers to entry.

This matters because many blockbuster biologic drugs are gradually losing patent protection across the world by 2030.

As these patents expire, companies like Biocon will come up with their generic version (a copy of that) at a lower cost. But biosimilars aren't the company's only growth engine.

A Hidden Business Within the Group:

Another important part of the Biocon story is Syngene, where the company owns roughly 52%.

Syngene operates as a CRDMO (Contract Research, Development and Manufacturing Organization), helping global pharmaceutical companies research, develop, and manufacture new medicines.

While Biocon focuses on selling therapies, Syngene benefits from the growing trend of pharmaceutical companies outsourcing research and manufacturing. Together, they give the group two different long-term growth engines.

The Acquisition That Changed Everything:

The biggest turning point for Biocon came in 2022. The company acquired Viatris' biosimilars business, a transformational deal that significantly expanded its global presence. However, growth came with a cost.

To finance the acquisition, Biocon raised nearly $1.5 billion of debt, resulting in a sharp increase in interest expenses. At the same time, depreciation also moved higher as the newly acquired assets were added to the balance sheet.

As a result, profitability came under pressure even though the business itself became much larger.

The Numbers Needed a Closer Look:

If you only looked at the reported profits in FY23 and FY24, the business appeared to be performing well. But there was an important detail.

Biocon reported other income of ₹853 crore in FY23 and ₹1,217 crore in FY24. These one-time gains made earnings look stronger than the underlying business performance. Excluding these gains, earnings growth during those years was much weaker and in some periods, even negative. This is a good reminder that reported profits don't always tell the complete story.

The Balance Sheet Tells the Same Story:

The acquisition also changed how efficiently the company used its assets.

Before the Viatris acquisition, Biocon generated an average asset turnover ratio of around 1.2x over five years. After the deal, that number dropped to nearly 0.4x.

At first glance, this may look concerning. But the decline largely reflects the addition of a massive asset base that has not yet reached its full earning potential. In other words, the assets have been built. Now they need to generate returns.

Why Management Believes the Story Is About to Change:

Management believes this investment phase is now nearing its end. Biocon currently has a pipeline of 20 biosimilar products, with 17 focused on oncology. Together, these products target an estimated $75 billion market opportunity, representing roughly 35% of the global oncology market.

Of course, a large opportunity doesn't automatically translate into revenue. Commercial success will depend on regulatory approvals, successful launches, market penetration, and execution. That's where the real challenge begins.

FY27 Could Be the Turning Point:

The company has already launched five biosimilars across FY25 and FY26. However, management expects the financial contribution from these launches to become far more meaningful from the second half of FY27 onwards, as adoption improves across key markets.

The heavy investment cycle is largely complete. That is why management describes FY27 as an "operational inflection point." The integration of the Viatris business is mostly behind them. Acquisition-related costs are reducing.

From here, the focus shifts to improving operating leverage, increasing asset utilisation, reducing debt, and converting a large product pipeline into sustainable earnings growth.

Our Takeaway:

Biocon has spent the last few years building the platform. It expanded globally, strengthened its biosimilar portfolio, built manufacturing capacity, and absorbed one of the biggest acquisitions in its history.

Now comes the more important phase: Can the company execute consistently, improve profitability, and generate strong returns from the assets it has spent years building?

The opportunity is certainly there. Over the next few years, execution, not expansion, will likely determine whether Biocon's next chapter becomes its most rewarding one.